n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2α and telomerase activity

[1]  H. Harn,et al.  The Induction of Orphan Nuclear Receptor Nur77 Expression by n-Butylenephthalide as Pharmaceuticals on Hepatocellular Carcinoma Cell Therapy , 2008, Molecular Pharmacology.

[2]  H. Harn,et al.  Orphan nuclear receptor, Nurr‐77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor , 2008, Journal of neurochemistry.

[3]  H. Harn,et al.  The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo3 , 2006, Journal of neurochemistry.

[4]  F. Domann,et al.  AP-2γ Induces p21 Expression, Arrests Cell Cycle, Inhibits the Tumor Growth of Human Carcinoma Cells , 2006 .

[5]  R. Britto,et al.  Apoptosis Induction by Activator Protein 2α Involves Transcriptional Repression of Bcl-2* , 2006, Journal of Biological Chemistry.

[6]  Walter Kolch,et al.  Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. , 2006, Cancer research.

[7]  F. Domann,et al.  AP-2gamma induces p21 expression, arrests cell cycle, and inhibits the tumor growth of human carcinoma cells. , 2006, Neoplasia.

[8]  H. Harn,et al.  The Antitumor Effects of Angelica sinensis on Malignant Brain Tumors In vitro and In vivo , 2005, Clinical Cancer Research.

[9]  T. Bito,et al.  Retinoic acid suppresses telomerase activity in HSC‐1 human cutaneous squamous cell carcinoma , 2005, The British journal of dermatology.

[10]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[11]  Dima Suki,et al.  Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  V. Kosma,et al.  Expression of HER2 and its association with AP-2 in breast cancer. , 2004, European journal of cancer.

[13]  R. Janknecht.  On the road to immortality: hTERT upregulation in cancer cells , 2004, FEBS letters.

[14]  S. Weitzman,et al.  Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer , 2004, Cancer Research.

[15]  L. Ellis,et al.  Activator Protein 2α Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer Cells , 2004, Cancer Research.

[16]  K. L. Kirkpatrick,et al.  hTERT Expression in Human Breast Cancer and Non-Cancerous Breast Tissue: Correlation with Tumour Stage and c-Myc Expression , 2003, Breast Cancer Research and Treatment.

[17]  L. Ellis,et al.  Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. , 2004, Cancer research.

[18]  M. Ueda,et al.  Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. , 2003, The Journal of investigative dermatology.

[19]  S. Goodison,et al.  Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells. , 2003, Molecular cancer research : MCR.

[20]  G. Fontanini,et al.  Evaluation of telomerase in the development and progression of colon cancer. , 2002, International journal of molecular medicine.

[21]  V. Kosma,et al.  Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Jaung-Geng Lin,et al.  The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. , 2001, Life sciences.

[23]  高尚德,et al.  The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest , 2001 .

[24]  V. Kosma,et al.  Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation , 2001, Journal of clinical pathology.

[25]  Jeffrey E Gershenwald,et al.  Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo , 2001, Oncogene.

[26]  A. Baldi,et al.  Expression of AP‐2 transcription factor and of its downstream target genes c‐kit, E‐cadherin and p21 in human cutaneous melanoma , 2001, Journal of cellular biochemistry.

[27]  V. Kosma,et al.  Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer , 2000, British Journal of Cancer.

[28]  K. Yasumoto,et al.  Prognostic impact of telomerase activity in non-small cell lung cancers. , 1999, Annals of surgery.

[29]  F. Jänicke,et al.  Differential telomerase activity, expression of the telomerase catalytic sub‐unit and telomerase‐RNA in ovarian tumors , 1999, International journal of cancer.

[30]  S. Kaye,et al.  Is small cell lung cancer the perfect target for anti-telomerase treatment? , 1999, Carcinogenesis.

[31]  박병준,et al.  유방종양에서의 Telomerase Activity , 1999 .

[32]  S. Kyo,et al.  hTERT is a critical determinant of telomerase activity in renal‐cell carcinoma , 1998, International journal of cancer.

[33]  J. McDougall,et al.  Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. , 1998, The American journal of pathology.

[34]  S. Han,et al.  Telomerase activity in lung cancer cell lines and tissues. , 1998, Lung cancer.

[35]  J. Gershenwald,et al.  Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.

[36]  E. Dmitrovsky,et al.  High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. , 1997, Journal of the National Cancer Institute.

[37]  Y. Katakura,et al.  Bidirectional regulation of telomerase activity in a subline derived from human lung adenocarcinoma. , 1997, Biochemical and biophysical research communications.

[38]  C B Harley,et al.  Telomerase catalytic subunit homologs from fission yeast and human. , 1997, Science.

[39]  June Corwin,et al.  Telomerase Catalytic Subunit Homologs from Fission Yeast and Human , 1997 .

[40]  Gregg B. Morin,et al.  Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT , 1997, Nature Genetics.

[41]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[42]  M. S. Rhyu.  Telomeres, telomerase, and immortality. , 1995, Journal of the National Cancer Institute.

[43]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[44]  E. Blackburn,et al.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis , 1989, Nature.

[45]  V A Zakian,et al.  Structure and function of telomeres. , 1989, Annual review of genetics.

[46]  E CARBONETTO,et al.  [Colon Cancer]. , 1958, El Dia medico.